Open AccessIn Vivo gp41 Antibodies Targeting the 2F5 Monoclonal Antibody Epitope Mediate Human Immunodeficiency Virus Type 1 Neutralization Breadth
Author(s) -
Xiaoying Shen,
Robert Parks,
David C. Montefiori,
Jennifer Kirchherr,
Brandon F. Keele,
Julie M. Decker,
William A. Blattner,
Feng Gao,
Kent J. Weinhold,
Charles B. Hicks,
Michael Greenberg,
Beatrice H. Hahn,
George M. Shaw,
Barton F. Haynes,
Georgia D. Tomaras
Publication year - 2009
Publication title -
journal of virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.617
H-Index - 292
eISSN - 1070-6321
pISSN - 0022-538X
DOI - 10.1128/jvi.02631-08
Subject(s) - epitope , monoclonal antibody , virology , gp41 , biology , neutralization , antibody , neutralizing antibody , heterologous , virus , immunology , gene , genetics
The broadly neutralizing human monoclonal antibodies (MAbs) 2F5 and 4E10, both targeting the highly conserved human immunodeficiency virus type 1 (HIV-1) envelope membrane proximal external region (MPER), are among the MAbs with the broadest heterologous neutralizing activity and are of considerable interest for HIV-1 vaccine development. We have identified serum antibodies from an HIV-infected subject that both were broadly neutralizing and specifically targeted MPER epitopes that overlap the 2F5 epitope. These MPER-specific antibodies were made 15 to 20 months following transmission and concomitantly with the development of autoantibodies. Our findings suggest that multiple events (i.e., genetic predisposition and HIV-1 immune dysregulation) may be required for induction of broadly reactive gp41 MPER antibodies in natural infection.